Table 1.
Demographic and clinical patient characteristics.
| Characteristic | Total | Centre 1 (TR‐MRDB) | Centre 2 (TP‐MRDB) |
|---|---|---|---|
| Biopsy‐naïve men, n (%) | 2597 (100) | 566 (22) | 2031 (78) |
| Age, years, median (IQR) | 66 (61–71) | 65 (60–69) | 67 (62–71) |
| DRE, n (%) | |||
| Normal* | 1205 (74) | 390 (70) | 815 (76) |
| Suspicious* | 434 (26) | 171 (30) | 262 (24) |
| Missing | 958 (37) | 5 (0.88) | 953 (47) |
| PSA level, ng/mL, median (IQR) | 6.3 (4.9–8.9) | 6.2 (4.6–9.6) | 6.4 (4.9–8.7) |
| Prostate volume MRI†, mL, median (IQR) | 62 (45–87) | 58 (42–79) | 64 (47–89) |
| Missing, n (%) | 9 (0.35) | – | 9 (0.44) |
| PSAD, ng/mL/mL, median (IQR) | 0.10 (0.07–0.15) | 0.11 (0.07–0.17) | 0.10 (0.07–0.14) |
| Missing, n (%) | 9 (0.35) | – | 9 (0.44) |
| mpMRI, n (%) | |||
| PI‐RADS 1–2 | 1467 (56) | 307 (54) | 1160 (57) |
| PI‐RADS 3 | 149 (5.7) | 30 (5.3) | 119 (5.9) |
| PI‐RADS 4 | 462 (18) | 104 (18) | 359 (18) |
| PI‐RADS 5 | 519 (20) | 125 (22) | 393 (19) |
| Method of biopsy, n (%) | |||
| No biopsy | 1488 (57) | 325 (57) | 1163 (57) |
| TR‐MRDB‐fusion | 137 (5.3) | 137 (24) | – |
| TR‐MRDB‐in‐bore | 100 (3.9) | 100 (18) | – |
| TP‐MRDB‐fusion | 830 (32) | – | 830 (41) |
| Only SB | 42 (1.6) | 4 (0.71) | 38 (1.9) |
| Biopsy cores MRDB, n, median (IQR) | 4 (3–6) | 3 (3–4) | 5 (4–7) |
| Biopsy cores, TP‐MRDB with RB, n, median (IQR) | 11 (7–12) | – | 11 (7–12) |
| Complications, n (%) | 7 (0.66) | 2 (0.84) | 5 (0.60) |
| UTI/urosepsis‡ | 5 (0.47) | 1 (0.42) | 4 (0.48) |
| Haemorrhage‡ | 1 (0.09) | 1 (0.42) | – |
| Acute urinary retention‡ | 1 (0.09) | – | 1 (0.12) |
| Positive biopsy cores, n, median (IQR) | |||
| MRDB | 3 (2–5) | 3 (2–3) | 4 (2–5) |
| RB | 2 (1–3) | – | 2 (1–3) |
| Histology, n (%) | |||
| MRDB | 1067 (41) | 237 (42) | 830 (41) |
| No MRDB | 1530 (59) | 329 (58) | 1201 (59) |
| No prostate cancer§ [+RB] | 198 (7.6) [176 (6.8)] | 40 (7.1) | 158 (7.8) [136 (6.7)] |
| Prostate cancer§ [+RB] | 869 (33) [891 (34)] | 197 (35) | 672 (33) [694 (34)] |
| GG 1 cancer§ [+RB] | 201 (7.7) [198 (7.6)] | 50 (8.8) | 151 (7.4) [148 (7.3)] |
| GG ≥2 cancer§ [+RB] | 668 (26) [693 (27)] | 147 (26) | 521 (26) [546 (27)] |
| GG ≥3 cancer§ [+RB] | 373 (14) [395 (15)] | 88 (16) | 285 (14) [307 (15)] |
| Histology, n (%) | |||
| SB | 42 (1.6) | 4 (0.71%) | 38 (1.9) |
| No prostate cancer‡ | 26 (62) | 3 (75) | 23 (61) |
| Prostate cancer‡ | 16 (38) | 1 (25) | 15 (39) |
| GG 1 cancer‡ | 12 (29) | – | 12 (32) |
| GG ≥2 cancer‡ | 4 (9.5) | 1 (25) | 3 (7.9) |
| GG ≥3 cancer‡ | 1 (2.4) | – | 1 (2.6) |
Percentages may not total 100 because of rounding. *% of available characteristic; †prostate volume was measured on MRI; ‡% of total/cohort MRDB; §numbers/% including RB cores (within square brackets).